Cargando…

Plasma apixaban levels in Chinese patients with chronic kidney disease—Relationship with renal function and bleeding complications

Introduction: Accumulation of apixaban in plasma is a major concern in patients with chronic kidney disease (CKD). Studies that investigated plasma apixaban level in CKD patients and its association with clinically significant events are scarce. Methods: Patients with CKD Stage 1–4 who were taking a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sin, Chun-fung, Wong, Ka-ping, Wong, Tsz-fu, Siu, Chung-wah, Yap, Desmond Y. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772439/ https://www.ncbi.nlm.nih.gov/pubmed/36569289 http://dx.doi.org/10.3389/fphar.2022.928401

Ejemplares similares

Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease—Relationships With Renal Function and Clinical Events
por: Sin, Chun-Fung, et al.
Publicado: (2022)

WATCHMAN device-related thrombus successfully treated with apixaban: A case report
por: Wong, Chun-Ka, et al.
Publicado: (2017)

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events
por: Attelind, Sofia, et al.
Publicado: (2022)

Apixaban: Gastrointestinal bleeding: case report
Publicado: (2021)

Effect of Apixaban Pretreatment on Alteplase-Induced Thrombolysis: An In Vitro Study
por: Thalerová, Sandra, et al.
Publicado: (2021)

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation
por: Mukai, Yutaro, et al.
Publicado: (2017)

Apixaban Causing Hepatic Cystic Bleeding: A Rare but a Life-Threatening Complication
por: Shehi, Elona, et al.
Publicado: (2021)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

ADPKD, COVID-19, and Apixaban: The Treacherous Intracystic Bleeding − A Letter on Apixaban Causing Hepatic Cystic Bleeding by Shehi et al.
por: Sergi, Consolato M.
Publicado: (2022)

Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries
por: Villari, Ambra, et al.
Publicado: (2017)

Page Kidney Complicating Kidney Biopsy after Stopping Apixaban: A Physician's Dilemma
por: Onuigbo, Macaulay A. C., et al.
Publicado: (2020)

Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation
por: Limcharoen, Sutee, et al.
Publicado: (2022)

Combination of Wogonin and Artesunate Exhibits Synergistic anti-Hepatocellular Carcinoma Effect by Increasing DNA-Damage-Inducible Alpha, Tumor Necrosis Factor α and Tumor Necrosis Factor Receptor-Associated Factor 3-mediated Apoptosis
por: Chen, Minting, et al.
Publicado: (2021)

Tetramethylpyrazine: An Active Ingredient of Chinese Herbal Medicine With Therapeutic Potential in Acute Kidney Injury and Renal Fibrosis
por: Li, Jun, et al.
Publicado: (2022)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Ultrasound-Guided Lauromacrogol Injection for the Treatment of Active Bleeding After Renal Biopsy
por: Liu, Weizong, et al.
Publicado: (2021)

Lumbar Artery Bleed as a Complication of Percutaneous Renal Biopsy and a Proposed Workflow for Massive Bleeding
por: Ngoh, Clara Lee Ying, et al.
Publicado: (2018)

International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study
por: Ofek, Fanny, et al.
Publicado: (2019)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
por: Grymonprez, Maxim, et al.
Publicado: (2023)

Apixaban/enoxaparin-sodium/parnaparin-sodium: Muscle bleeding, haemoptysis and gastrointestinal bleeding: 5 case reports
Publicado: (2021)

The contribution of apixaban renal clearance to total clearance
por: Frost, Charles, et al.
Publicado: (2015)

Selective Estrogen Receptor Modulator-Like Activities of Herba epimedii Extract and its Interactions With Tamoxifen and Raloxifene in Bone Cells and Tissues
por: Zhou, Liping, et al.
Publicado: (2021)

Massive Spontaneous Hemothorax as a Complication of Apixaban Treatment
por: Abu Hishmeh, M., et al.
Publicado: (2018)

Impact of contrast-induced acute kidney injury on long-term major adverse cardiovascular events and kidney function after percutaneous coronary intervention: insights from a territory-wide cohort study in Hong Kong
por: Ng, Andrew Kei-Yan, et al.
Publicado: (2021)

High Plasma Exposure of Statins Associated With Increased Risk of Contrast-Induced Acute Kidney Injury in Chinese Patients With Coronary Artery Disease
por: Cai, Liyun, et al.
Publicado: (2018)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients
por: Fung, Winston Wing-Shing, et al.
Publicado: (2023)

Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage
por: Yen, Hung-Wen
Publicado: (2019)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
por: Kim, Hamin, et al.
Publicado: (2023)

Incidence, Prediction, and Outcomes of Major Bleeding After Percutaneous Coronary Intervention in Chinese Patients
por: Ng, Andrew Kei-Yan, et al.
Publicado: (2022)

Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice
por: Yeung, Martin Ho Yin, et al.
Publicado: (2022)

Association Between Chinese Herbal Medicine Therapy and the Risk of Chronic Kidney Disease in Gout Patients
por: Xiao, Yan-Zhuan, et al.
Publicado: (2021)

Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan
por: Sung, Fung-Chang, et al.
Publicado: (2022)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
por: Lee, Juseung, et al.
Publicado: (2023)

Selected Topical Agents Used in Traditional Chinese Medicine in the Treatment of Minor Injuries- A Review
por: Leung, Ping-chung, et al.
Publicado: (2016)

Construction of a risk scoring system using clinical factors and RYR2 polymorphisms for bleeding complications in patients on direct oral anticoagulants
por: Jang, Eun Jeong, et al.
Publicado: (2023)

Mechanisms and Efficacy of Chinese Herbal Medicines in Chronic Kidney Disease
por: Zhao, Mingming, et al.
Publicado: (2021)

Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients
por: Mansell, Holly, et al.
Publicado: (2022)

Apixaban Dosing in Patients With Kidney Failure Treated With Peritoneal Dialysis
por: Lidgard, Benjamin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ri2obhr7bbp5c7n7qga61ocoar